Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768963 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for the Inhibition of Neovascularization in Pterygia
A Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00768963 is a Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 10 participants.
The verdict
NCT00768963, a Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.
Interventions
- DRUG ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768963
The ClinicalTrials.gov registry entry for NCT00768963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ranibizumab is the first listed.
NCT00768963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768963 about?
NCT00768963 is a clinical study titled "Ranibizumab for the Inhibition of Neovascularization in Pterygia". The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.
What is the current status of trial NCT00768963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00768963?
The interventions under investigation include: ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00768963?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.